‌$Novavax(NVAX)$‌Novavax has shipped its first shipment to US!https://www.mea.gov.in/vaccine-supply.htm

‌$Novavax(NVAX)$‌Novavax Statement on European Medicines Agency Nuvaxovid™ Label Update Related to Allergic ReactionJul 14, 2022 Today, the European Medicines Agency (EMA) updated the label for our COVID-19 vaccine (NVX-CoV2373) to include the risk of severe allergic reactions. This update is a warning commonly included for commercially available vaccines, including COVID-19 vaccines. Novavax’ clinical development program reported no severe allergic reactions and therefore, this risk was not listed in the initial product label. With broader deployment of doses, we have received reports of two cases of anaphylaxis (allergic reaction) that met a probable/definite case definition. Because anaphylaxis can occur with all vaccines and based on these cases

$Tesla Motors(TSLA)$Was hoping that the fortune tellers are right... where is my $400???? Maybe after share split...😂😂

‌$Novavax(NVAX)$‌India's SII to halve output of AstraZeneca vaccine (not novavax)About 200 million doses of COVID-19 vaccine are gathering dust in warehouses of the world’s largest vaccine manufacturer as global demand ebbs. Serum Institute of India (SII) stopped making new COVID-19 vaccine doses in December, CEO Adar Poonawalla said at the India Economic Conclave, as quoted by Bloomberg. The company currently sits on a stockpile of 200 million doses, he said.Sourceshttps://www.fiercepharma.com/pharma/200m-unused-doses-astrazenecas-covid-vaccine-partner-serum-institute-halts-production#:~:text=With%20200M%20unused%20doses%2C%20AstraZeneca's%20COVID%20vaccine%20partner%20Serum%20Institute%20halts%20production,-By%20Angus%20Liu&text=About%2020

$Tesla Motors(TSLA)$Why did it go up so much??? I was hoping to buy 100 shares at $400each! 😂😂😂Fortunately I bought some at shares yesterdayand enjoyed the rally. I am pretty sure some fortune teller would come and say be careful or the rally is going to collapse and $400 will come soon. I have hearing $400 is coming soon for a very long time... 

‌$Novavax(NVAX)$‌New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine CongressNovavax will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress (WVC) in Washington, DC, April 18 - 21, 2022. In addition, the latest data on its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at both WVC and the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in in Lisbon, Portugal, April 23 - 26, 2022. Data from eight abstracts and presentations, including four oral presentations, will be presented across the two congresses.NanoFlu identifies a recombinant h

‌$Novavax(NVAX)$‌Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India1. First authorization of Novavax' COVID-19 vaccine in adolescent population received 2. Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to <18 in India3. Authorization highlights immunogenicity and reassuring safety profile of Covovax in Phase 2/3 study of Indian adolescents aged ≥12 to <18 and data from an ongoing Phase 3 pediatric expansion trial of NVX-CoV2373 in adolescents aged ≥12 to <18 in the U.S.Extracted from:https://ir.novavax.com/2022-03-22-Novavax-and-

‌$Novavax(NVAX)$‌3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall StreetNovavax: Implied upside of 257% The first COVID-19 play that offers drool-worthy upside, at least according to one Wall Street analyst, is biotech stock Novavax ( NVAX -13.36% ). Despite a $50 price-target reduction in February, B. Riley analyst Mayank Mamtani still believes Novavax can reach $265 a share. This represents a cool 257% upside from where shares ended last week. Mamtani's aggressive price target is based on a few factors. For instance, he believes that concerns over Novavax's near-term manufacturing struggles are overblown. Mamtani explained months ago that Novavax was nearing its monthly manufacturing target of around 150 million doses, and wo